Tablets & Capsules


Issue link:

Contents of this Issue


Page 7 of 63

6 April 2018 Tablets & Capsules research Researchers accelerate drug release profile of 3D-printed tablets LONDON, UK—Selective laser sintering (SLS)—a 3D printing tech- nology used to manufacture plastic, metallic, or ceramic products—can also be used to produce orally disin- tegrating printlets (3D tablets) with accelerated drug release properties, according to findings by researchers a t U n i v e r s i t y C o l l e g e L o n d o n School of Pharmacy. During the study, researchers separately mixed 5 percent paracetamol (the model drug) with hydroxypropyl methylcel- lulose (HPMC E5) and vinylpyrroli- d o n e - v i n y l a c e t a t e c o p o l y m e r (Kollidon VA 64). The findings show that the release characteristics of the printlets can be altered by modulat- ing SLS printing parameters. By employing faster laser scanning speeds, researchers were able to accelerate the drug-release profile of the HPMC and Kollidon formula- tions. This study was published in the International Journal of Pharmaceutics. markets API market to exceed $210 billion by 2021 NORTHBROOK, IL—An increase of chronic disease incidences and the rising prevalence of cancer will spur growth in the global active pharma- ceutical ingredient (API) market, resulting in a compound annual growth rate of 6.3 percent through 2021, according to a report by MarketsandMarkets. Other factors driving market growth include tech- nological advancements in API manu- facturing, the growing importance of generics, a rapidly increasing geriatric population, increased abbreviated new drug applications (ANDAs) and increasing uptake of biopharmaceuti- cals. The market is forecast to reach $210.97 billion at the end of the fore- cast period. The North American seg- ment is expected to dominate the API market, with the US holding major market share. The report identifies Pfizer, Novartis International, Sanofi, Boehringer Ingelheim, Bristol-Myers Squibb, Teva Pharmaceutical, Eli Lilly, GlaxoSmithKline, Merck, and AbbVie as key players in the API market. industry news FDA publishes DSCSA-related draft guidances SILVER SPRING, MD—The FDA published two draft guidances related to the agency's implementation of the Drug Supply Chain Security Act (DSCSA). The "Standardization of Data and Documentation Practices for Product Tracing" draft guidance expands on the standards for the interoperable exchange of transac-

Articles in this issue

Links on this page

Archives of this issue

view archives of Tablets & Capsules - TC0418